Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; disodium edetate; benzalkonium chloride; octoxinol 40; sodium hydroxide; hydrochloric acid; purified water - acular eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis. acular eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ketorolac trometamol 30 mg/ml - solution for injection - 30 mg/ml - active: ketorolac trometamol 30 mg/ml excipient: ethanol hydrochloric acid sodium chloride sodium hydroxide water for injection - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral* formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (conversion from intramuscular to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. * ketorolac oral formulation is available from other brands. ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ketorolac trometamol 5 mg/ml;  ;   - eye drops, solution - 0.5% w/v - active: ketorolac trometamol 5 mg/ml     excipient: benzalkonium chloride disodium edetate dihydrate hydrochloric acid macrogols purified water sodium chloride sodium hydroxide

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; benzalkonium chloride; octoxinol 40; sodium hydroxide; water for injections; disodium edetate; hydrochloric acid - ketorolac medicianz eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis.,ketorolac medicianz eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: water for injections; benzalkonium chloride; octoxinol 40; hydrochloric acid; sodium chloride; disodium edetate; sodium hydroxide - ketorolac medsurge eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic,conjunctivitis.,ketorolac medsurge eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - ear drops, solution - excipient ingredients: benzalkonium chloride; hydrochloric acid; sodium hydroxide; disodium edetate; octoxinol 40; water for injections; sodium chloride - ketorolac mlabs eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis.,ketorolac mlabs eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; ethanol - ketorolac trometamol solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period.,patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dosage and administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage form can be available from other brand/s.,general,ketorolac trometamol solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac trometamol solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dose and method of administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).